Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses

Pediatrics

Volumn 127, Issue 1, 2011, Pages 77-84

  Widdice, Lea E ^a   Bernstein, David I ^a   Leonard, Anthony C ^b   Marsolo, Keith A ^a   Kahn, Jessica A ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

African Americans; Contraception; Immunization; Insurance coverage; Logistic models; Medical specialty; Medication adherence; Papillomavirus infections; Papillomavirus vaccines; Patient compliance; Pregnancy; Uterine cervical neoplasms; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GROUPS BY AGE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; SCHOOL CHILD; VACCINATION; VERRUCA VULGARIS;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78650798840     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0812     Document Type: Article

References (45)

1. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927
2. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet. 2007;369(9574):1693-1702
3. FUTURE II Study Group; Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007;369(9576):1861-1868
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943 (Pubitemid 46740303)
5. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135-2145
6. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-209 (Pubitemid 46340765)
7. Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med. 2000;18(1S):97-140
8. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years: United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(36):997-1001
9. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24
10. Gardasil [package insert] 9682302RR-2. Whitehouse Station, NJ: Merck and Co Inc; 2006
11. Phillips KA, Morrison KR, Andersen R, Aday LA. Understanding the context of healthcare utilization: assessing environmental and provider-related variables in the behavioral model of utilization. Health Serv Res. 1998;33(3 pt 1):571-596
12. Andersen RM. National health surveys and the behavioral model of health services use. Med Care. 2008;46(7):647-653
13. Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273-1302 (Pubitemid 30075409)
14. Andersen RM, Davidson PL. Improving Access to Care in America. In: Andersen RM, Rice TH, Kominski GF, eds. Changing the US Health Care System. 3rd ed. San Francisco, CA: Jossey-Bass; 2007:3-31
15. Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of quadrivalent HPV Vaccine. 2006. Available at: www.cdc.gov/nip/recs/provisional-recs/hpv.pdf. Accessed August 19, 2006
16. Immunization Action Coalition. Ask the experts: general vaccine questions. 2009. Available a t : www.immunize.org/askexperts/experts-general. asp.2009. Accessed August 5, 2009
17. Glantz SA. Primer of Biostatistics. 6th ed. San Francisco, CA: McGraw-Hill; 2005:257
18. Vittinghoff E, Glidden DV, Shiboski SC, Mc- Culloch CE. Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models. New York, NY: Springer Science+Business Media Inc; 2005:41
19. Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt). 2009;18(10):1679-1686
20. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2009;84(10):864-870
21. Wong VK, Woodruff C, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Pediatr Infect Dis J. 1994;13(10):936
22. Gonzalez IM, Averhoff FM, Massoudi MS, et al. Hepatitis B vaccination among adolescents in 3 large health maintenance organizations. Pediatrics. 2002;110(5):929-934
23. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99 (suppl 2):S389-S397
24. Kollar LM, Rosenthal SL, Biro FM. Hepatitis B vaccine series compliance in adolescents. Pediatr Infect Dis J. 1994;13(11):1006-1008
25. Middleman AB, Robertson LM, Young C, Durant RH, Emans SJ. Predictors of time to completion of the hepatitis B vaccination series among adolescents. J Adolesc Health. 1999;25(5):323-327
26. Centers for Disease Control and Prevention. ACIP provisional recommendations for HPV vaccine. Available at: www.cdc.gov/ vaccines/recs/ provisional/downloads/hpvvac-dec2009-508.pdf. Accessed January 12, 2010
27. Sabidó M, Gavalda L, Olona N, Ramon JM. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. Vaccine. 2007;25(43):7568-7572
28. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999;103(6 pt 1):1243-1247 (Pubitemid 29258800)
29. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis. 1989;160(5):766-769
30. Middleman AB. Race/ethnicity and gender disparities in the utilization of a school-based hepatitis B immunization initiative. J Adolesc Health. 2004;34(5):414-419
31. Rand CM, Shone LP, Albertin C, Auinger P, Klein JD, Szilagyi PG. National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med. 2007;161(3):252-259
32. Irwin CE Jr, Adams SH, Park MJ, Newacheck PW. Preventive care for adolescents: few get visits and fewer get services. Pediatrics. 2009;123(4). Available at: www.pediatrics.org/cgi/content/full/123/4/e565
33. Stokley S, Freed G, Curtis R, et al. Adolescent vaccination: recommendations from the National Vaccine Advisory Committee. Am J Prev Med. 2009;36(3):278-279
34. Szilagyi PG, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era? Pediatrics. 2008;121(suppl 1):S15-S24
35. Schaffer SJ, Fontanesi J, Rickert D, et al. How effectively can health care settings beyond the traditional medical home provide vaccines to adolescents? Pediatrics. 2008;121(suppl 1):S35-S45
36. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 2010;28(4):989-995
37. Neubrand TP, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila). 2009;48(9):966-969
38. Moore-Caldwell SY, Werner MJ, Powell L, Greene JW. Hepatitis B vaccination in adolescents: knowledge, perceived risk, and compliance. J Adolesc Health. 1997;20(4):294-299 (Pubitemid 27164628)
39. SEER. SEER cancer statistics review, 1975-2006. SEER stat fact sheets cervix uteri. Available at: http://seer.cancer.gov/statfacts/html/cervix.html. Accessed August 10, 2009
40. Kentucky Cancer Registry. Available at: www.kcr.uky.edu. Accessed July 1, 2009
41. American Cancer Society, Ohio Department of Health. Ohio Cancer Facts and Figures 2009. Columbus, OH: Ohio State University; 2009
42. Prislin R, Dyer JA, Blakely CH, Johnson CD. Immunization status and sociodemographic characteristics: the mediating role of beliefs, attitudes, and perceived control. Am J Public Health. 1998;88(12):1821-1826 (Pubitemid 29017998)
43. Cates JR, Brewer NT, Fazekas KI, Mitchell CE, Smith JS. Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, southern women. J Rural Health. 2009;25(1):93-97
44. Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev. 2009;18(2):363-372
45. Seid M, Simmes DR, Linton LS, Leah CE, Edwards CC, Peddecord KM. Correlates of vaccination for hepatitis B among adolescents: results from a parent survey. Arch Pediatr Adolesc Med. 2001;155(8):921-926